CA3063140A1 - Biodegradable microparticles for sustained delivery of anti-angiogenic peptide - Google Patents

Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Download PDF

Info

Publication number
CA3063140A1
CA3063140A1 CA3063140A CA3063140A CA3063140A1 CA 3063140 A1 CA3063140 A1 CA 3063140A1 CA 3063140 A CA3063140 A CA 3063140A CA 3063140 A CA3063140 A CA 3063140A CA 3063140 A1 CA3063140 A1 CA 3063140A1
Authority
CA
Canada
Prior art keywords
microparticle
seq
peptide
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3063140A
Other languages
English (en)
French (fr)
Inventor
Jordan J. Green
Niranjan Pandey
Aleksander S. Popel
Peter A. Campochiaro
Jayoung Kim
Raquel LIMA E. SILVA
Ron SHMUELI
Adam Mirando
Original Assignee
Johns Hopkins University
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Asclepix Therapeutics Inc filed Critical Johns Hopkins University
Publication of CA3063140A1 publication Critical patent/CA3063140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3063140A 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Abandoned CA3063140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (1)

Publication Number Publication Date
CA3063140A1 true CA3063140A1 (en) 2018-11-15

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063140A Abandoned CA3063140A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Country Status (8)

Country Link
US (1) US20200179285A1 (https=)
EP (1) EP3621597A4 (https=)
JP (1) JP2020518651A (https=)
KR (1) KR20200003859A (https=)
CN (1) CN111315364A (https=)
AU (1) AU2018266690A1 (https=)
CA (1) CA3063140A1 (https=)
WO (1) WO2018208829A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021056B1 (pt) 2017-04-06 2022-11-22 Sustain Holdings, Llc Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
AU2020248438A1 (en) 2019-03-26 2021-10-28 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP3958889B1 (en) 2019-04-22 2025-01-08 Sustain Holdings, LLC Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.

Also Published As

Publication number Publication date
US20200179285A1 (en) 2020-06-11
WO2018208829A1 (en) 2018-11-15
KR20200003859A (ko) 2020-01-10
WO2018208829A8 (en) 2019-07-04
JP2020518651A (ja) 2020-06-25
EP3621597A4 (en) 2021-06-02
EP3621597A1 (en) 2020-03-18
AU2018266690A1 (en) 2019-12-12
CN111315364A (zh) 2020-06-19

Similar Documents

Publication Publication Date Title
US20200179285A1 (en) Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
Lin et al. Stimulus‐responsive hydrogel for ophthalmic drug delivery
US20130084277A1 (en) Formulations of active agents for sustained release
EP3424948B1 (en) Vascular endothelial growth factor targeting peptide-elastin fusion polypeptide and self-assembling nanostructure, which are for inhibiting angiogenesis
US20080085276A1 (en) Method of treating eye injury with local administration of a VEGF inhibitor
MX2007003789A (es) Suministro ocular de formulaciones polimericas para suministro.
CN109072241A (zh) 具有改善的玻璃体内半衰期的组合物及其用途
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
CN110234336A (zh) 用于促性腺激素释放激素(GnRH)拮抗剂的长效释放的组合物和方法
Rana et al. Recent trends in drug delivery and emerging biomedical applications of gelatin for ophthalmic indications
JP2022507627A (ja) ポリ－アラニンｃ－ドメインのサブセグメントを有する単鎖インスリンアナログ
US20160030628A1 (en) Treatment for bile leakage
ES2205481T3 (es) Microparticulas biodegradables para la liberacion sostenida de farmacos terapeuticos.
Pescina et al. Therapeutics and carriers: the dual role of proteins in nanoparticles for ocular delivery
JP2020518651A5 (https=)
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
CN101396347A (zh) 一种重组人血管内皮抑制素缓释微球的制备方法
CN105873570A (zh) 治疗性蛋白质的持续释放储槽式调配物和其用途
Dahiya et al. Ocular delivery of peptides and proteins
KR20140130725A (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
US20240226241A1 (en) Formulations for intraocular delivery of peptides derived from type iv collagen
WO2005040195A2 (en) Formulation of exendins
WO2025259913A2 (en) Peptide-modified ppcn and methods of ocular delivery and treatment of disease therewith
Eskandari et al. ÔØ Å ÒÙ× Ö ÔØ
Kapoor et al. Long-Acting Intraocular Delivery Approaches for Biological Therapy of Age-Related Macular Degeneration

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231109